Fertility Supplements Market

How big is Fertility Supplements Market in 2026?

The fertility supplements market is valued at USD 3.2 billion in 2026 and is projected to reach USD 6.8 billion by 2036, expanding at a CAGR of 7.8% over the 2026–2036 period.

Sales of fertility supplements are estimated to rise at 7.8% CAGR through 2036. Market valuation increases from USD 3.0 billion in 2025 to USD 3.2 billion in 2026 and is estimated to reach USD 6.8 billion by 2036. More people are planning nutrition before conception, and supplements are becoming part of fertility-care routines. Brands are making doses and claims easier to understand so buyers know each formula's role. In November 2025, the World Health Organization reported that infertility affects about one in six people of reproductive age. That care population is bringing more people into pregnancy planning and earlier preconception nutrition discussions.

Country conditions are creating different buying paths even though fertility goals are similar. In the UK, many patients are paying part or all of their fertility treatment costs themselves. In June 2026, the UK fertility regulator reported that public funding covered 28% of IVF treatment cycles in 2024. That funding mix is making households compare supplement costs with clinic fees and other fertility expenses. Japan uses public insurance for infertility treatment, while nutrition products remain separate purchases. South Korea is funding fertility tests and treatment support, bringing more adults into formal care. USA shoppers are finding products easily but are facing strict federal rules for health claims. German buyers are comparing fertility products with familiar vitamin supplements in pharmacies and drugstores. These care systems are changing what buyers can afford and how much proof they expect.

Key Takeaways

• Fertility care is bringing more people into pregnancy planning and is creating earlier demand for nutrition products tied to clear routines.
• Within type, blend holds 55.8% in 2026 because one formula covers several nutrition goals during pregnancy planning.
• Capsules account for 41.1% of form demand in 2026 because fixed doses are making multi-ingredient routines easier to follow.
• Men represent 67.2% of end users in 2026 as sperm-health testing is giving nutrition products a clearer preconception role.
• The World Health Organization's November 2025 infertility guideline is keeping supplements separate from treatment and is limiting stronger claims without better outcome evidence.
• Bayer, Theralogix, FairHaven Health, Pharmavite and Legacy are serving buyers through large nutrition brands and fertility-focused business models.

Analyst Perspective

"Male fertility testing is creating a clearer nutrition opportunity as more men are discussing sperm health before conception. Manufacturers need simple formula evidence because clinicians are asking what each product supports before recommending nutrition beside fertility care."

- Nandini Roy Choudhury, Principal Consultant, Future Market Insights.

How is the fertility supplements market segmented?

The fertility supplements market is segmented: by Type, Form, End Users, and Region. Blend leads the Type category with 55.8% of 2026 demand, Capsules lead the Form category with 41.1% of 2026 demand, and Men lead the End Users category with 67.2% of 2026 demand.

The market uses type, form, end users and region as four primary segmentation axes. Type includes blend, natural and synthetic products made for fertility-focused supplement formulas. Form covers capsules, soft gels, liquids, powders and other delivery formats that buyers are using. End users include men and women who are choosing products for fertility or pregnancy planning. Region groups demand across seven areas with different care systems, retail channels and regulatory rules.

What makes blend central to the type category?

Blend products combine several nutrients in one planned routine, making daily use easier for buyers. Formulators are combining vitamins and minerals with antioxidants and inositol inside the same product. Buyers are comparing one label and one dose plan instead of managing several separate fertility products.

• Within type, blend is expected to hold 55.8% in 2026. Buyers are choosing blends because one formula can cover several nutrition goals during pregnancy planning.
• In March 2026, Bayer launched an updated Elevit blend in Japan with folate and more vitamin D for women planning pregnancy. The formula is showing how brands are combining several nutrients inside one daily preconception product.

Why do capsules lead the form category?

Capsules give buyers fixed doses without the mixing or flavor issues that come with liquids and powders. Brands are dividing complex formulas across capsules while keeping the daily plan simple to follow. Buyers are following the same routine for months without measuring or mixing each dose themselves.

• In 2026, capsules are projected to represent 41.1% of form demand. Fixed doses are making multi-ingredient routines easier for buyers to follow each day. Brands are dividing complex formulas without asking buyers to measure powders or liquids.
• FairHaven Health is selling FH PRO Women in capsules with a set daily plan for fertility support during pregnancy planning.

How do men shape the end users category?

Male-focused products address sperm-health needs during fertility testing and pregnancy planning. Semen tests are giving men specific results they can discuss with doctors. Brands are positioning nutrition beside fertility care without presenting supplements as medical treatment. Clear ingredient lists are helping buyers compare formulas with the concern identified during testing.

• Men are estimated to hold 67.2% of end users in 2026. Sperm-health testing is helping male buyers discuss nutrition around a defined fertility concern.
• In November 2025, the World Health Organization made no recommendation for or against antioxidant supplements for infertile men with abnormal semen test results. That position is limiting stronger claims that antioxidant supplements improve male fertility outcomes.

What are the drivers, restraints and opportunities in the fertility supplements market?

In the fertility supplements market, the key driver is pregnancy planning that supports demand, the key restraint is strict claim rules that limit stronger messages, and the key opportunity is male fertility testing that creates clearer uses for targeted nutrition.

• Driver: More buyers are considering supplements as they begin fertility testing and plan nutrition before conception.
• Restraint: Limited clinical proof and strict claim rules are limiting stronger messages about fertility outcomes.
• Opportunity: Male fertility testing is linking sperm-health concerns with clearer product use and clinician guidance.

People are considering supplements while they plan a pregnancy and arrange fertility tests. Doctors are using prenatal nutrition guidance to explain nutrient needs before and during pregnancy. In April 2025, the National Institutes of Health updated its prenatal supplements fact sheet for doctors and other health workers. Couples are using the guidance to decide whether a supplement belongs beside tests or medical care. Men are entering the same planning process through semen testing and sperm-health discussions. Brands are serving both paths with formulas tied to a clear nutrition goal. Simple dose instructions are helping people follow the plan for several months. Clear claims are keeping nutrition support separate from promises to diagnose or treat infertility.

Brands are facing strict claim rules because dietary supplements cannot promise to diagnose or treat infertility. The Food and Drug Administration requires evidence for claims about supporting normal body functions. Covered health-support claims need a standard legal disclaimer under U.S. supplement law. In December 2025, the Food and Drug Administration reminded supplement makers how that disclaimer must appear with those claims. Strong health wording is creating legal risk when product evidence does not support the stated effect. Stores and doctors are asking for records they can check during product reviews. Weak evidence is slowing store review and reducing doctor confidence in the product. Clear claim limits are helping brands explain nutrition support without presenting supplements as infertility treatment.

Male fertility testing is connecting supplements to a clearer need because semen analysis can identify a specific sperm-health concern. Legacy is placing its male supplement beside home semen testing and sperm storage services. Men are using test results to discuss a defined concern before choosing nutrition support. Doctors are using those results to explain product timing and follow-up care. Multi-month plans align with sperm development without presenting supplements as treatment. Testing is reducing guesswork by linking product use to a known fertility concern. Brands are supporting this route with simple doses and evidence for each formula. A measured concern is helping doctors explain how nutrition fits within a broader fertility plan.

Which country CAGRs are included in the fertility supplements market?

Country	CAGR
South Korea	9.7%
UK	9.4%
Japan	8.9%
USA	8.5%
Germany	8.2%

How do country-level CAGRs compare in the fertility supplements market?

Within the fertility supplements market, South Korea is projected to grow at 9.7% CAGR through 2036, followed by the UK at 9.4%, Japan at 8.9%, the USA at 8.5%, and Germany at 8.2%. Care access and payment rules are creating different fertility supplement buying routes across the five countries. Public programs are shaping access in South Korea and Japan while private payment is affecting many UK fertility decisions. USA and Germany combine broad retail access with strict rules for reproductive-health claims on supplements.

• South Korea’s public fertility programs are bringing adults into testing and care, placing preconception nutrition beside care planning.
• Private-pay fertility care in the UK is making households weigh supplement spending against clinic fees and treatment costs.
• Japan’s insurance coverage is keeping infertility care inside clinics, giving pharmacies a clear role for separate nutrition purchases.
• Across the USA, broad retail and online access is making accurate product claims and supporting evidence more important.
• German pharmacy channels are keeping product evidence and claim wording central during preconception supplement selection and counseling.

Buyers are weighing supplement cost, pharmacy access and claim evidence differently under each national fertility-care system.

Country-wise Analysis

• By 2036, South Korea demand is projected to grow at 9.7% CAGR. Public fertility programs are bringing more adults into testing and treatment as they plan a pregnancy. The national support program covers ovarian reserve tests for women and semen tests for men. In August 2026, the Ministry of Data and Statistics reported 254,300 births during 2025. Public support is keeping fertility care visible and is giving clinics more chances to discuss nutrition beside medical plans. The programs do not prove that supplements improve fertility outcomes. Brands need doses and claims that match each formula's stated nutrition role. Clear labels are helping clinics discuss products without presenting them as substitutes for medical care.
• Fertility supplement sales in the UK are forecast to expand at 9.4% CAGR by 2036. Private treatment costs are shaping supplement choices because National Health Service funding varies by location and who qualifies. In September 2026, the Office for National Statistics reported a 1.39 total fertility rate for England and Wales during 2025. Many patients are paying clinic fees themselves and are comparing supplements with treatment costs. Weak evidence is making an extra fertility product harder to justify beside those bills. Pharmacy access is making comparison easy but is increasing the need for simple labels and product evidence. Products with clear timing and nutrition roles are giving self-funded patients a better basis for choice.
• Japan is estimated to post 8.9% CAGR over the forecast period. Public insurance is keeping infertility treatment inside clinic care for more patients. Most buyers are paying for supplements separately because nutrition products sit outside insurance-covered treatment. Pharmacy staff are explaining doses and product information during store visits. In June 2026, Japan's Ministry of Health, Labour and Welfare reported a 1.14 total fertility rate during 2025. That figure gives national family-planning context while supplement purchases remain separate from insured care. Brands must avoid suggesting that supplements replace medical care during fertility treatment. Shoppers are comparing fertility products with common vitamins during the same pharmacy visit. Simple labels are helping staff explain product use beside clinic care.
• By 2036, USA fertility supplement demand is projected to grow at 8.5% CAGR. Buyers are finding products through stores and online shops across a broad retail base. In April 2026, the Centers for Disease Control and Prevention reported 3,606,400 births in the United States during 2025. The birth count gives national family-planning context while supplement demand depends on claims, access and buyer needs. Federal rules allow claims about supporting normal body functions but bar promises that supplements diagnose or treat infertility. Online sales are making consistent wording important because buyers can compare many product claims within minutes. Consistent claims are helping retailers and clinicians discuss the same product across sales channels.
• Fertility supplement sales in Germany are forecast to expand at 8.2% CAGR by 2036. Drugstores and pharmacies are placing fertility products beside familiar vitamins for easy comparison. European Union rules limit how brands can describe health benefits on supplement packs. Buyers need evidence that matches each claim printed on the label. In July 2026, Germany's Federal Statistical Office reported a 1.32 total fertility rate during 2025. That fertility rate gives national context while product purchases depend on pharmacy access and claim support. Weak evidence is making broad fertility claims harder for brands to defend. Simple dose notes are helping pharmacy staff explain what a product supports and what it does not treat.

Who are the notable companies in the fertility supplements market?

Notable companies in the fertility supplements market include Bayer, Theralogix, FairHaven Health, Pharmavite, and Legacy.

Bayer and Pharmavite are reaching pregnancy-planning buyers through familiar prenatal brands sold across broad retail networks. Theralogix and FairHaven Health are focusing on formulas made for male and female fertility needs. Legacy is reaching men through semen testing, sperm storage and a linked supplement rather than a broad prenatal range. These business models are changing what buyers see first during fertility planning. Retail brands are making products easy to find in familiar stores. Fertility specialists are giving buyers detailed ingredient and dose information for defined concerns. Legacy is starting with a measured sperm-health need and is connecting that result to services and nutrition.

• Theralogix and FairHaven Health are selling male and female products with clear dose and ingredient information for fertility planning.
• Bayer and Pharmavite are using established brands and broad store access for preconception and prenatal nutrition needs.
• Legacy is placing its male supplement beside semen testing and sperm storage within one connected fertility-care route.

Competitive Benchmarking: Fertility Supplements Market

Company	Fertility-Specific Formulation Breadth	Male and Female Preconception Coverage	Quality and Clinical Substantiation	Geographic Reach
Bayer	High	High	Medium	Global consumer-health footprint; Elevit and Menevit evidenced in Australia and Asia-Pacific
Theralogix	High	High	High	United States and Canada; selected international availability
FairHaven Health	High	High	High	United States direct sales; international distributor network across Europe, Asia, Africa and Oceania
Pharmavite	Medium	Low	High	United States retail and direct-to-consumer reach through Nature Made
Legacy	Low	Low	Medium	United States male-fertility platform and direct-to-consumer reach

The first column shows how many products each company sells specifically for fertility or pregnancy planning. The second shows whether each company offers products for both men and women. The quality column uses public evidence from certifications, studies and doctor review. A High rating means the company has broad public evidence for that category. A Medium rating means public evidence is useful but narrower. A Low rating marks a clear documented limit in that category. Ratings use current product, quality and distribution information from public sources.

Key Developments in the Fertility Supplements Market

• In May 2026, Solaray launched Liposomal Prenatal for women's health needs before and during pregnancy. The product is giving buyers another prenatal format alongside standard daily supplement options.
• In April 2026, TIES launched Foundations for men seeking fertility and performance support during pregnancy planning. The formula is giving male buyers one defined option linked to sperm-health and preconception needs.
• In March 2026, Theralogix launched OvaNAD+ for women planning pregnancy and seeking support for egg health. The product is expanding Theralogix's fertility range with an ovarian-health option rather than another general prenatal formula.

Key Players in the Fertility Supplements Market

Fertility-Specialist Formulation Platforms

• Theralogix
• FairHaven Health

Scaled Consumer Preconception Nutrition

• Bayer
• Pharmavite

Male-Fertility Platform-Linked Nutrition

• Legacy

Fertility Supplements Market - Report Scope

Coverage field	Report scope
Market breakdown	Type, Form, End Users, and Region
Quantitative Units	USD billion
Market Definition	Revenue includes ingested supplements sold for fertility, reproductive health, or nutrition before pregnancy. The scope excludes prescription fertility drugs, diagnostic tests, fertility procedures, and sperm or egg storage. The scope excludes general wellness supplements without fertility positioning and care revenue earned after the supplement sale.
Regions Covered	North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa
Countries Covered	Japan, UK, South Korea, Germany, USA
Key Companies Profiled	Bayer, Theralogix, FairHaven Health, Pharmavite, Legacy
Forecast Period	2026 to 2036
Approach	Primary and secondary research with cross-checking across multiple sources.

Fertility Supplements Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Fertility Supplements Market by Segments

Fertility Supplements Market segmented by Type:

• Blend
• Natural
• Synthetic

Fertility Supplements Market segmented by Form:

• Capsules
• Soft Gels
• Liquids
• Powders
• Others

Fertility Supplements Market segmented by End Users:

• Men
• Women

Fertility Supplements Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• World Health Organization. (2025, November 28). Guideline for the prevention, diagnosis and treatment of infertility.
• World Health Organization. (2025, November 28). Treatment of infertility due to male factors.
• National Institutes of Health, Office of Dietary Supplements. (2025, April 3). Dietary Supplements and Life Stages: Pregnancy - Health Professional Fact Sheet.
• U.S. Food and Drug Administration. (2025, December 11). Letter to the Dietary Supplement Industry on the DSHEA Disclaimer.
• U.S. Food and Drug Administration. (n.d.). Questions and Answers on Dietary Supplements. Retrieved September 24, 2026.
• Centers for Disease Control and Prevention, National Center for Health Statistics. (2026, April 9). U.S. Births down 1% in 2025.
• Office for National Statistics. (2026, September 8). Births in England and Wales: 2025 (final rates).
• Ministry of Health, Labour and Welfare, Japan. (2026, June 3).
• Ministry of Health, Labour and Welfare, Japan. (n.d.). Retrieved September 24, 2026.
• Ministry of Health and Welfare, Republic of Korea. (n.d.). Retrieved September 24, 2026.
• Ministry of Data and Statistics, Republic of Korea. (2026, August 26). 2025
• German Federal Statistical Office (Destatis). (2026, July 1). Total fertility rate drops to 1.32 children per woman in 2025.
• Human Fertilisation and Embryology Authority. (n.d.). Costs and funding. Retrieved September 24, 2026.
• Bayer Yakuhin. (2026, March 19).
• Bayer Yakuhin. (2026, September 9).
• Elevit Australia / Bayer. (n.d.). Menevit Pre-conception Sperm Health. Retrieved September 24, 2026.
• Theralogix. (2026, March 10). Theralogix Introduces OvaNAD+ Egg Quality Support: An Innovative NAD+ Supplement for Reproductive and Ovarian Health.
• Theralogix. (2025, January 21). Theralogix Launches Ovasitol Plus: Advanced Support for Metabolic and Hormonal Health.
• Theralogix. (n.d.). Fertility Health. Retrieved September 24, 2026.
• Theralogix. (n.d.). ConceptionXR Reproductive Health For Men. Retrieved September 24, 2026.
• Theralogix. (n.d.). TheraNatal OvaVite Preconception Supplement. Retrieved September 24, 2026.
• FairHaven Health. (n.d.). FH PRO Fertility Multivitamin For Women. Retrieved September 24, 2026.
• FairHaven Health. (n.d.). FH PRO Fertility Multivitamin For Men. Retrieved September 24, 2026.
• FairHaven Health. (n.d.). Fertility Supplements. Retrieved September 24, 2026.
• Nature Made. (2025, June 19). Nature Made Prenatal Vitamins are Safe, Efficacious, and High Quality.
• Nature Made. (n.d.). Prenatal Multivitamins Softgels + Choline Capsules. Retrieved September 24, 2026.
• SwimClub. (2025, September 25). Introducing SwimClub: The First Clinically-Formulated Male Fertility Supplement.
• Legacy. (n.d.). Male Fertility Supplement. Retrieved September 24, 2026.
• Legacy. (n.d.). Frequently asked questions. Retrieved September 24, 2026.
• Nature's Bounty. (2026, May 5). Support Egg Quality and Ovulation with Nature's Bounty New Fertility Supplement.
• HumanCo Investments. (2026, April 28). Introducing TIES: A Foundational Men's Fertility and Performance Brand, Backed by $1.5M Seed Round Led by HumanCo and Jason H. Karp.
• FullWell. (2026, May 6). FullWell Launches Strawberry-Flavor Capsule-Free Prenatal Stick Packs.
• O Positiv Health. (2026, June 10). O Positiv Health Releases Its First Prenatal, PREGGO Prenatal + Probiotic [Corrected release; original issued February 10, 2026].
• FairHaven Health. (n.d.). Retailers & Distributors. Retrieved September 24, 2026.
• SmartyPants Vitamins. (2026, March 16). SmartyPants Vitamins Launches New OB-GYN Co-Developed Prenatal Capsule Designed To Support Baby's Brain and Development.
• Human Fertilisation and Embryology Authority. (2026, June 16). Fertility treatment 2024: Trends and figures.
• Bayer. (2025, September 1). Bayer launches Supradyn Mom's and Supradyn Naturals Calcium+: A first-of-its-kind prenatal nutrition range to address critical nutrient gaps in maternal health.
• Solaray. (2026, May 4). Solaray launches liposomal prenatal to redefine daily nutrition for moms-to-be.

The bibliography gives readers a selected reference list, while the full report contains the complete source list and detailed citations.

This Report Answers

• How large is the Fertility Supplements Market in 2026 and what value is projected for 2036?
• Which fertility-care and preconception conditions support supplement demand during or beside clinical treatment?
• Why does blend lead the type category among fertility supplement formulation strategies during 2026?
• Why do capsules lead the form category for measured multi-ingredient fertility supplement routines in 2026?
• How do country growth rates differ across South Korea, UK, Japan, USA and Germany through 2036?
• Which companies sell fertility-focused or preconception products across consumer and specialist channels?
• Which evidence and regulatory conditions limit stronger claims or slow fertility supplement purchasing decisions?
• What should buyers evaluate while choosing fertility supplements for a defined preconception nutrition routine?